RED
BANK, N.J., Oct. 13,
2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:
PRVB), a biopharmaceutical company dedicated to intercepting and
preventing immune-mediated disease, today announced that it will
report its third quarter 2022 financial results on Thursday, November 3, 2022, before the opening of
the U.S. financial markets. The company will host a conference call
at 8:00am E.T. to discuss its
financial results and provide a company update.
To access the call, please dial 1-888-347-7861 (domestic) or
1-412-902-4247 (international) ten minutes prior to the start
time and ask to be connected to the "Provention Bio Call." An audio
webcast will also be available on the "Events and Webcasts" page of
the Investors section of the Company's
website, www.proventionbio.com. An archived webcast will be
available on the Company's website approximately two hours after
the conference call.
About Provention Bio, Inc.
Provention Bio, Inc.
(Nasdaq: PRVB) is a biopharmaceutical company focused on
advancing the development of investigational therapies that may
intercept and prevent debilitating and life-threatening
immune-mediated diseases. The Biologics License Application (BLA)
for teplizumab, its lead investigational drug candidate, for the
delay of progression to Stage 3 clinical type 1 diabetes in at-risk
individuals has been filed by the U.S. Food and Drug Administration
(FDA). The Company's pipeline includes additional clinical-stage
product candidates that have demonstrated in pre-clinical or
clinical studies proof-of-mechanism and/or proof-of-concept in
other autoimmune diseases, including celiac disease and lupus.
Visit www.ProventionBio.com for more information and
follow us on Twitter: @ProventionBio.
Internet Posting of Information
Provention Bio, Inc.
uses its website, www.proventionbio.com, as a means of
disclosing material nonpublic information and for complying with
its disclosure obligations under Regulation F.D. Such disclosures
will be included on the Company's website in the "News" section.
Accordingly, investors should monitor this portion of the Company's
website, in addition to following its press releases, SEC filings
and public conference calls and webcasts.
Investor Contact:
Kristen Kelleher, Investor
Relations
investorrelations@proventionbio.com
Media Contact:
Kaelan Hollon, VP of
Communications
khollon@proventionbio.com
202-421-4921
View original content to download
multimedia:https://www.prnewswire.com/news-releases/provention-bio-to-report-third-quarter-2022-financial-results-on-november-3-2022-301646538.html
SOURCE Provention Bio, Inc.